Zydus receives final approval from the USFDA for Exemestane Tablets

Ahmedabad, 05 October, 2018

Zydus Cadila has received the final approval from the USFDA to market Exemestane Tablets, (US RLD – AROMASIN® Tablets), 25 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The estimated sale for Exemestane Tablets is $68.6 million (Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2018, extracted September 2018.)

Exemestane belongs to the group of medicines called 'aromatase inhibitor'. It is used in women after menopause for the treatment of early breast cancer (cancer that has not spread outside the breast) in women who have cancer that needs the female hormone estrogen to grow, have had other treatments for breast cancer for 2-3 years and are switching to Exemestane to complete 5 years in a row of hormonal therapy. It is also used in the treatment of advanced breast cancer (cancer that has spread) after treatment with other therapies, where it has not benefitted the patient or is no longer effective.

The group now has 220 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***